Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 26 descriptions
No. | 薬物名(臨床試験情報から抽出) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 150 mg double-blinded secukinumab (Cosentyx (TN)) | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬1. 150 mg double-blinded secukinumab
| 1件: IL17A IL17A 💬1. 150 mg double-blinded secukinumab
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 271 271 💬1. 150 mg double-blinded secukinumab
| |||||||||||||||||||||||||||||||||||
2 | 150 mg open-label secukinumab (Cosentyx (TN)) | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬2. 150 mg open-label secukinumab
| 1件: IL17A IL17A 💬2. 150 mg open-label secukinumab
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 271 271 💬2. 150 mg open-label secukinumab
| |||||||||||||||||||||||||||||||||||
3 | 300 mg double-blinded secukinumab (Cosentyx (TN)) | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬3. 300 mg double-blinded secukinumab
| 1件: IL17A IL17A 💬3. 300 mg double-blinded secukinumab
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 271 271 💬3. 300 mg double-blinded secukinumab
| |||||||||||||||||||||||||||||||||||
4 | Cosentyx | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬4. Cosentyx
| 1件: IL17A IL17A 💬4. Cosentyx
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 4件: 41 41, 107, 269, 271 💬
| |||||||||||||||||||||||||||||||||||
5 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA COSENTYX- 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) ... | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬5. COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA
| 1件: IL17A IL17A 💬5. COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 107 107 💬5. COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA
| |||||||||||||||||||||||||||||||||||
6 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE COSENTYX- 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) ... | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬6. COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE
| 1件: IL17A IL17A 💬6. COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 107 107 💬6. COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE
| |||||||||||||||||||||||||||||||||||
7 | Cosentyx 300 mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬7. Cosentyx 300 mg solution for injection in pre-filled syringe
| 1件: IL17A IL17A 💬7. Cosentyx 300 mg solution for injection in pre-filled syringe
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 41 41 💬7. Cosentyx 300 mg solution for injection in pre-filled syringe
| |||||||||||||||||||||||||||||||||||
8 | Cosentyx 300mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬8. Cosentyx 300mg solution for injection in pre-filled syringe
| 1件: IL17A IL17A 💬8. Cosentyx 300mg solution for injection in pre-filled syringe
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 41 41 💬8. Cosentyx 300mg solution for injection in pre-filled syringe
| |||||||||||||||||||||||||||||||||||
9 | Cosentyx® | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬9. Cosentyx®
| 1件: IL17A IL17A 💬9. Cosentyx®
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 269 269 💬9. Cosentyx®
| |||||||||||||||||||||||||||||||||||
10 | SECUKINUMAB (Cosentyx (TN)) | 1件: Secukinumab Secukinumab (Cosentyx) | 1件: Secukinumab
Secukinumab
(Cosentyx (TN)) 💬10. SECUKINUMAB
| 1件: IL17A IL17A 💬10. SECUKINUMAB
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 8件: 13 13, 37, 41, 46, 107, 160, 269, 271 💬10. SECUKINUMAB
|